Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 13, Issue 6, Pages 879-893Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.2012.667074
Keywords
zolpidem; benzodiazepines; insomnia; sleep; hypnotics
Categories
Funding
- Transcept Pharmaceuticals, Inc.
- Sanofi
- Somnus Therapeutics, Inc.
- Cephalon
- Orexo
- Somaxon
- Sepracor
Ask authors/readers for more resources
Introduction: The imidazopyridine derivative zolpidem, which acts as a benzodiazepine (BZ) receptor agonist, is the most widely prescribed hypnotic drug in the US. Areas covered: This review addresses the neuroreceptor properties of zolpidem; clinical pharmacokinetics, pharmacodynamics and drug interactions; efficacy as a hypnotic; adverse effects; tolerance, dependence and withdrawal; relation to motor vehicle accidents and complex sleep behaviors; and new dosage forms. Expert opinion: Approved doses of zolpidem (10 mg for adults, 5 mg for the elderly) are consistently effective in reducing sleep latency and consequently increasing sleep duration in patients with insomnia. However, favorable effects on sleep maintenance are observed less consistently. Residual daytime effects are unlikely with recommended doses, and provided that at least 8 h elapse prior to arising. Hypnotic efficacy is maintained with repeated nightly use, and the risk of rebound insomnia is low. Dependence and abuse of zolpidem are no more likely to occur than with typical benzodiazepines. Newly available novel dosage forms of zolpidem have increased therapeutic options for patients with insomnia variants such as sleep maintenance insomnia and middle-of-the-night awakening.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available